期刊文献+

伊马替尼治疗的慢性髓系白血病患者JARID1B、Hes1和MMP-9基因表达水平差异的研究 被引量:2

Expression Levels of JARID1B,Hes1 and MMP-9 Genes in CML Patients Treated with Imatinib Mesylate
下载PDF
导出
摘要 目的:探讨JARID1B、Hes1和MMP-9基因表达水平与慢性髓系白血病(chronic myelogenous leukemia,CML)疾病的病程阶段及伊马替尼(imatinib mesylate,IM)疗效的关系。方法:收集湖北医药学院附属太和医院血液科CML患者25例(慢性期15例、进展期10例)和体检中心正常人15例的外周血标本。按初次确诊为CML患者的病期和服用IM后的疗效分组(有效组和无效组),采用实时定量RT-PCR方法检测JARID1B、Hes1和MMP-9基因mRNA表达水平,分析JARID1B、Hes1和MMP-9基因表达水平差异与疾病阶段及IM疗效的相关性。结果:初次确诊未服用IM慢性期和进展期CML患者Hes1和MMP-9基因的表达水平明显高于正常人(P<0.05);CML患者慢性期JARID1B基因的表达水平与正常人相比无明显差异(P=0.20),进展期患者JARID1B的表达水平明显高于正常人(P<0.05);IM治疗有效组JARID1B和Hes1基因的表达水平与无效组相比无明显差异(P=0.85、P=0.82),MMP-9的表达水平有效组明显低于无效组(P<0.05)。结论:JARID1B、Hes1和MMP-9基因的表达水平与CML的不同病程分期有关;JARID1B、Hes1基因表达水平与IM疗效无关,MMP-9基因表达水平与IM疗效有关。 Objective:To explore the relationship between the expression levels of JARID1B,Hes1 and MMP-9 genes and the stages of chronic myelogenous leukemia( CML) and the curative effect of imatinib mesylate ( IM).Methods:Peripheral blood samples of 15 cases of CML in chronic phase and 10 cases of CML in progressive phase were collected from the Hematology Department of Taihe Hospital affiliated to Hubei University of Medicine and 15 cases of healthy people in the Physical Examination Center.CML patients were divided into effective group and ineffective group based on the efficacy after treatment with IM,then real-time PCR was used to detect the expression levels of JARID1B,Hes1 and MMP-9 mRNA,finally,the differences in the level of gene expression and their correlations with CML stages and IM curative efficacy were analysed.Results:The expression levels of Hes1 and MMP-9 in initially diagnosed patients in chronic and progressive phase without IM treatment were significantly higher than those of health people( P < 0.05). There was no significant difference in the expression level of JARID1B between chronic phase patients and health people ( P > 0.05),but the expression level of JARID1B in the progressive phase patients was higher than that of health people ( P < 0.05).The expression levels of JARID1B and Hes1 in the IM-effective group were not significantly different from those in the IM-ineffective group ( P = 0.85,P = 0.82),while the expression level of MMP-9 in the IM-effective group was significantly lower than that in the IM-ineffective group( P < 0.05).Conclusion:The expression levels of JARID1B, Hes1 and MMP-9 relate with the different phase of CML;The expression levels of JARID1B and Hes1 have not significant relationship with IM curative efficacy,the MMP-9 gene expression level relates with IM curative efficacy.
作者 何志凯 薛燊 张勇洪 李琳 夏云金 汪香 石鑫 刘瑜 许争 李琛 张璟璇 HE Zhi-Kai;XUE Seng;ZHANG Yong-Hong;LI Lin;XIA Yun-Jin;WANG Xiang;SHI Xin;LIU Yu;XU Zheng;LI Chen;ZHANG Jing-Xuan(Institute of Basic Medical Sciences,School of Basic Medical Sciences,Hubei University of Medicine,Shiyan 442000,Hubei Province,China;Department of Hematology,Taihe Hospital Affiliated to Hubei University of Medicine,Shiyan 442000,Hubei Province,China;Medical Research Institute,Wuhan University,Wuhan 430000,Hubei Province,China;Key Laboratory of Targeted Intervention of Cardiovascular Diseases,Department of Pathophysiology,Nanjing Medical University,Nanjing 210000,Jiangsu Province,China)
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2019年第4期1071-1076,共6页 Journal of Experimental Hematology
基金 湖北省教育厅中青年人才项目(Q20162114) 湖北医药学院自由探索基金(FDFR201609) 湖北省卫生健康科研基金(WJ2019M051) 湖北医药学院自然科学研究计划(2014QDJZR05、2017QDJZR19、2017QDJZR18)
关键词 伊马替尼 慢性髓系白血病 JARID1B HES1 MMP-9 imatinib mesylate chronic myelogenous leukemia JARID1B Hes1 MMP-9
  • 相关文献

参考文献4

二级参考文献25

  • 1陈燕华,王惠珍,陶慧清.恶性血液病住院病人生活质量及其影响因素的调查研究[J].南方护理学报,2005,12(8):12-14. 被引量:20
  • 2干定云,陈燕.慢性粒细胞白血病分子靶向治疗的新进展[J].临床血液学杂志,2006,19(3):190-192. 被引量:20
  • 3Reece-Smith AM,MacGoey P,Shah MA,et al.A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era[J].Eur J Surg Oncol,2012,38:484-489.
  • 4Shapiro SM.Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction(BIND)[J].J Perinatol,2004,25:54-59.
  • 5Melo JV,Chuah C.Resistance to imatinib mesylate in chronic myeloid leukaemia[J].Cancer Lett,2007,249:121-132.
  • 6Cortes JE,Kantarjian H,Shah NP,et al.Ponatinib in refractory Philadelphia chromosome-positive leukemias[J].New Engl J Med,2012,367:2075-2088.
  • 7Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials[J].Blood, 2006,108(5): 1478 - 1484.
  • 8O'Dwyer ME, Druker BJ. Chronic myelogenous leukaemia new thera- peutie prineiples[J]. J Intern Med, 2001, 250(1): 3-9.
  • 9Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and eytogenetic responses to imatinib mesylate in ehronie myelogenous leukemia[J]. N Engl J Med, 2002, 346(9): 645 -652.
  • 10O'Brien SG, Guilhot F, Goldman JM. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up : sustained survival, low rate of transformation and increased rate of major molecular response(MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM)[J]. Blood, 2008, 11201):76.

共引文献24

同被引文献15

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部